Close

Help us reach $1,000,000! Match My Donation

Nir Hacohen, Ph.D., Wade F. B. Thompson CLIP InvestigatorBroad Institute of MIT and Harvard

Support from CRI is empowering me to take on this basic question with the most modern tools available.
Area of Research: Lung Cancer, Melanoma, All Cancers

Checkpoint inhibitor immunotherapies have helped many patients by enabling anti-cancer T cells to remain active against tumors, but unfortunately these treatments are not always effective. Therefore, Dr. Hacohen’s work aims to understand why, and then overcome these obstacles to expand immunotherapy’s effectiveness to more patients. Specifically he’s characterizing how the tumor and immune cells evolve together over time in patients who respond initially, but then develop resistance. Already he’s identified mutations in the antigen presentation pathway that arise during treatment, as well as differences in immune cells between responders and non-responders. These findings will hopefully help guide the development of better predictive methods as well as treatment for these patients.

My personal goal is to deeply understand how the immune system recognizes cancers and eliminates it, and then to use that knowledge to develop increasingly specific and powerful therapies to control cancer. Support from CRI is empowering me to take on this basic question with the most modern tools available.
Let's spread the word about Immunotherapy! Click to share this page with your community.
Copy Link

*Immunotherapy results may vary from patient to patient.

Contact Us

Cancer Research Institute | National Headquarters
29 Broadway, 4th Floor | New York, NY 10006-3111

(800) 992-2623(212) 832-9376Staff Directory

Stay Connected with CRI

Follow us
Top